[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-340891-105":59,"doc-detail-340891-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","an-fc-modified-monoclonal-antibody-as-novel-treatment-option-for-pancreatic-cancer-brief-research-report","An Fc-modiﬁed monoclonal antibody as novel treatment option for pancreatic cancer - Brief Research Report","","Pancreatic cancer is a lethal disease with limited treatment options, creating an urgent need for novel therapies. Monoclonal antibodies improve outcomes by triggering antibody-dependent cellular cytotoxicity (ADCC), which depends on Fc-engineering to raise affinity for the Fc receptor CD16 on natural killer (NK) cells. This report presents preclinical characterization of a B7-H3 (CD276)-directed Fc-modified monoclonal antibody carrying S239D/I332E substitutions (B7-H3-SDIE), evaluating antigen-dependent NK activation, degranulation, cytokine release, and cytotoxicity against pancreatic cancer cells. Results support B7-H3-SDIE as a promising agent.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/an-fc-modified-monoclonal-antibody-as-novel-treatment-option-for-pancreatic-cancer-brief-research-report/340891/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/an-fc-modified-monoclonal-antibody-as-novel-treatment-option-for-pancreatic-cancer-brief-research-report/340891.png","ImageObject",300,407,{"name":92,"@type":93},"Himbo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What therapeutic limitation motivates this study for pancreatic cancer?","Question",{"text":112,"@type":113},"Pancreatic cancer has an unfavorable prognosis and most patients are not eligible for curative surgical resection. Systemic chemotherapy and existing targeted or immune strategies provide limited benefits, creating a need for new options.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does B7-H3-SDIE differ from an unmodified monoclonal antibody?",{"text":117,"@type":113},"It targets B7-H3 (CD276) and includes Fc amino acid substitutions S239D/I332E to increase affinity for the activating Fc receptor CD16 on NK cells.",{"name":119,"@type":110,"acceptedAnswer":120},"What preclinical effects were observed with B7-H3-SDIE?",{"text":121,"@type":113},"The antibody effectively activates NK cells against pancreatic cancer cells in an antigen-dependent manner, shown by NK activation, degranulation, and cytokine release, and it leads to significant tumor cell lysis in both short-term and long-term cytotoxicity assays.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},340891,1790693277,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},687197100911,"https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1785132997149421697","TYPE Brief Research Report PUBLISHED 22 January 2024  \nDOI 10.3389/fimmu.2024.1343929  \nOPEN ACCESS  \nEDITED BY Ping Wang,  \nMichigan State University, United States  \nREVIEWED BY Jinda Fan,  \nMichigan State University, United States Simona Sivori,  \nUniversity of Genoa, Italy  \n*CORRESPONDENCE Ilona Hagelstein  \n [ilona.hagelstein@med.uni-tuebingen.de](ilona.hagelstein@med.uni-tuebingen.de)  \nRECEIVED 24 November 2023  \nACCEPTED 08 January 2024  \nPUBLISHED 22 January 2024  \nCITATION  \nLutz MS, Wang K, Jung G, Salih HR and Hagelstein I (2024) An Fc-modiﬁed monoclonal antibody as novel treatment option for pancreatic cancer. Front. Immunol. 15:1343929 .  \ndoi: 10.3389/fimmu.2024.1343929  \nCOPYRIGHT  \n© 2024 Lutz, Wang, Jung, Salih and Hagelstein. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nAn Fc-modiﬁed monoclonal antibody as novel treatment option for pancreatic cancer  \nMartina S. Lutz 1,2, Kevin Wang 1, Gundram Jung 2,3, Helmut R. Salih 1,2 and Ilona Hagelstein 1,2*  \n1Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tuebingen, Tuebingen, Germany, 2Cluster of Excellence iFIT (EXC 2180) “ Image-Guided and Functionally Instructed Tumor Therapies”, University of Tuebingen, Tuebingen, Germany, 3 Department of Immunology, Eberhard Karls Universität Tübingen, Tuebingen, Germany  \nPancreatic cancer is a highly lethal disease with limited treatment options. Hence, there is a considerable medical need for novel treatment strategies. Monoclonal antibodies (mAbs) have signiﬁcantly improved cancer therapy, primarily due to their ability to stimulate antibody-dependent cellular cytotoxicity (ADCC), which plays a crucial role in their therapeutic efﬁcacy. As a result, signiﬁcant effort has been focused on improving this critical function by engineering mAbs with Fc regions that have increased afﬁnity for the Fc receptor CD16 expressed on natural killer (NK) cells, the major cell population that mediates ADCC in humans. Here we report on the preclinical characterization of a mAb directed to the target antigen B7-H3 (CD276) containing an Fc part with the amino acid substitutions S239D/I332E to increase afﬁnity for CD16 (B7-H3-SDIE) for the treatment of pancreatic cancer. B7-H3 (CD276) is highly expressed in many tumor entities, whereas expression on healthy tissues is more limited. Our ﬁndings conﬁrm high expression of B7-H3 on pancreatic cancer cells. Furthermore, our study shows that B7-H3-SDIE effectively activates NK cells against pancreatic cancer cells inan antigen-dependent manner, as demonstrated by the analysis of NK cell activation, degranulation and cytokine release. The activation of NK cells resulted in signiﬁcant tumor cell lysis in both short-term and long-term cytotoxicity assays. In conclusion, B7-H3-SDIE constitutes a promising agent for the treatment of pancreatic cancer.  \nKEYWORDS  \npancreatic cancer, B7-H3, NK cells, therapeutic antibody, immunotherapy  \nAbbreviations: 7-AAD, 7-aminoactinomycin D; ADCC: antibody dependent cellular cytotoxicity; CD, cluster of differentiation; E:T, effector-to-target; EU, endotoxin; IFN-g, Interferon g; IgG1, Immunglobulin G1; mAb: monoclonal antibody; MFI, median ﬂuorescence intensity; NK, natural killer; PBMC, peripheral blood mononuclear cells; PCR, polymerase chain reaction; PE, phycoerythrin; SD, standard deviation; TCGA, the Cancer Genome Atlas; TNF, tumor necrosis factor.  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \nIntroduction  \nPancreatic cancer is a highly aggressiv","cbCaioyBG2t1Dckn","https://ap.wps.com/l/cbCaioyBG2t1Dckn","pdf",3406774,12,"English","# Introduction\n## Rationale for Fc engineering to enhance CD16 affinity\n## Pancreatic cancer treatment limitations\n# Study overview and key findings\n## NK cell activation and ADCC mechanisms\n## Antigen-dependent cytotoxicity in short- and long-term assays","[{\"question\":\"What therapeutic limitation motivates this study for pancreatic cancer?\",\"answer\":\"Pancreatic cancer has an unfavorable prognosis and most patients are not eligible for curative surgical resection. Systemic chemotherapy and existing targeted or immune strategies provide limited benefits, creating a need for new options.\"},{\"question\":\"How does B7-H3-SDIE differ from an unmodified monoclonal antibody?\",\"answer\":\"It targets B7-H3 (CD276) and includes Fc amino acid substitutions S239D/I332E to increase affinity for the activating Fc receptor CD16 on NK cells.\"},{\"question\":\"What preclinical effects were observed with B7-H3-SDIE?\",\"answer\":\"The antibody effectively activates NK cells against pancreatic cancer cells in an antigen-dependent manner, shown by NK activation, degranulation, and cytokine release, and it leads to significant tumor cell lysis in both short-term and long-term cytotoxicity assays.\"}]","An Fc-modiﬁed monoclonal antibody as novel treatment option for pancreatic cancer - Brief Research Report | PDF",1790039374,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/deb7b9dfcdf13a02698a673591cdc61a.webp",983,1389,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f1ae8ee47608bafbb290f90a32a2e051.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/93ef2995db3c6040876214348b08861a.webp",981,1386,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a5c2de25d93fb76967c890491c36ba7c.webp",980,1385]